Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not

2026-02-20 07:30:47 ET

In January, I rated Corcept Therapeutics ( CORT ) a Hold , citing severe binary risk of its looming patent appeal against Teva Teva Pharmaceutical Industries ( TEVA ). On February 19th, the US Court of Appeals for the Federal Circuit affirmed the lower court's ruling, siding with Teva. As a consequence, a generic version of Corcept's drug Korlym will soon be on the market, calling into question all of Corcept's sales....

Read the full article on Seeking Alpha

For further details see: